---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-131786"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:26:14.097452+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PepGen reports positive Phase 2 FREEDOM2 data for PGN-EDODM1 in DM1; splicing correction 22.9% ex-outlier

## Summary
- 5 mg/kg cohort (n=8): mean splicing correction 7.3% overall, 22.9% excluding outlier; placebo 6.8%.
- No serious adverse events; all TEAEs mild/moderate; nausea most common; no renal toxicity.
- Middle finger vHOT showed improvement trend vs placebo worsening; returned to baseline at Week 16.
- 10 mg/kg cohort >50% enrolled; data expected 2H 2026; cash sufficient into 2H 2027.
- Mean muscle PGN-EDODM1 concentration 158 ng/g in 5 of 6 treated patients (one pending).

## SEC filing metadata
- accession: 0001193125-26-131786
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000119312526131786/0001193125-26-131786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000119312526131786/pepg-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-131786
- JSON: https://secwatch.observer/filing/0001193125-26-131786.json
- Plain text: https://secwatch.observer/filing/0001193125-26-131786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.